Global Payments Leader, Credorax, Rebrands As ‘Finaro’
Leading smart payments provider and merchant acquiring bank, Credorax, has today announced its new company identity, Finaro .
Focusing on its core pillars of creating multi-dimensional solutions to simplify payments and going the extra mile for its merchants, Finaro empowers global commerce by providing the ideal solution for cross-border businesses with its cutting-edge technology and superior support.
The news of the rebranding bookends a strong 2021, with Finaro’s impressive 40% Year-on-Year Compound Annual Growth Rate. Founded in 2009, the company currently employs over 350 people, and is based in Israel and Malta, with presence in China Mainland, Hong Kong, the United States and across Europe.
Credorax has already been proven as a payments provider that facilitates its merchants’ growth and with the global fintech industry expected to skyrocket to $190bn by 2026, this rapidly accelerating trajectory creates the perfect environment for Finaro’s new brand to establish itself as a strong player amongst its peers. This huge growth in fintech has seen cross-border sales take more than a quarter of the entire ecommerce marketplace in Europe, highlighting the significance of a provider that can make multidimensional payments brilliantly simple.
Finaro serves over 5000 merchants around the world and in a wide variety of industries, including retail, digital goods and services, travel, hospitality, and mobility. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile and Hero Gaming are among its customers and across all verticals the trend is similar: all merchants are operating within very competitive markets and they are required to create perfect customer experiences. Led by a team of payments experts and solution-creators, Finaro is committed to absorbing the immense complexity of payments and delivering simplicity, so merchants are free to pursue their ambition, knowing they are covered.
“Our company success has always been built on our in-house, cutting-edge full stack platform as well as strong customer relationships, and constant product innovation. Our passionate team of solutions-creators with a can-do approach enable us to create brilliantly simple payment solutions for our merchants, said Igal Rotem, Chief Executive Officer for Finaro.
“Our evolution from Credorax to Finaro reflects the revolution our business has undertaken since joining the payments world 15 years ago and our rebranding is the next step in our growth as a company and on our path towards realizing our vision of commerce, untethered. I’m incredibly proud reveal our new brand identity as Finaro,” Igal continued.
“We came into this industry with a fresh view because we saw obstacles that needed getting beyond, and that’s what we have been doing ever since,” commented Moshe Selfin, Chief Operating & Chief Technology Officer for Finaro. “We pioneered a multidimensional approach to payments that untangles even the most wicked problems in the payments space, paving the way for new and exciting possibilities and giving our merchants a meaningful competitive advantage.”
“Branding is much more than just colours, logos and slogans - it’s about the essence of our company and how we are presented to the world externally. When developing our new brand Finaro, we crystalized our essence, and it was critical to establish our identity as a company that cares about its customers and can deliver the outstanding,” explains Achiya Fried, Chief Commercial Officer of Finaro, “We go the extra mile in flexibility and we co-create solutions with our clients, by providing cutting edge, multidimensional payments solutions, that untangle the complexity of payments. Our new brand, Finaro, reflects just that."
###ENDS###
About Finaro
Finaro is a global cross-border payment provider empowering international commerce through brilliantly simple payments. Our passionate team, exceptional tech capabilities, product innovation, and customer-centric approach enables us to simplify complexity and create multidimensional solutions that generate growth and enable peace of mind for our merchants. To learn more, visit www.finaro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005805/en/
Contact information
Jenna Walker
jenna@skyparlour.com
07591 382 856
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom